Valirx (VAL) RNS Announcements

Add to Alert list
Date Time Source Announcement
13 Jun 2019 07:00 AM
RNS
Placing, Subscription Agreement & Issue of Warrant
10 Jun 2019 07:00 AM
RNS
Subscription Agreement Update
05 Jun 2019 07:00 AM
RNS
Notice of AGM & Update of Subscription Agreement
31 May 2019 11:07 AM
RNS
Subscription Agreement Update
31 May 2019 10:42 AM
RNS
Holding(s) in Company
30 May 2019 10:30 AM
RNS
Holding(s) in Company
29 May 2019 11:44 AM
RNS
Holding(s) in Company
29 May 2019 07:00 AM
RNS
Final Results
28 May 2019 07:00 AM
RNS
Subscription Agreement Update
23 May 2019 12:02 PM
RNS
Holding(s) in Company
22 May 2019 07:00 AM
RNS
Subscription Agreement Update
13 May 2019 02:00 PM
RNS
Price Monitoring Extension
02 May 2019 07:00 AM
RNS
Acquisition of Intellectual Property& JV Agreement
29 Apr 2019 02:06 PM
RNS
Second Price Monitoring Extn
29 Apr 2019 02:01 PM
RNS
Price Monitoring Extension
29 Apr 2019 11:07 AM
RNS
Second Price Monitoring Extn
29 Apr 2019 11:01 AM
RNS
Price Monitoring Extension
29 Apr 2019 10:55 AM
RNS
Holding(s) in Company
26 Apr 2019 07:00 AM
RNS
Subscription, Convertible Funds and Warrant Issue
15 Apr 2019 07:15 AM
EQS
Valirx (VAL): VAL401 is going forward
26 Mar 2019 07:00 AM
RNS
ValiSeek Update
21 Mar 2019 07:00 AM
RNS
Update on VAL201 & VAL301 Development Progress
21 Feb 2019 11:22 AM
RNS
Placing, Issue of Equity and Warrant
31 Jan 2019 07:00 AM
RNS
New patent grant allowances for VAL301
11 Jan 2019 07:00 AM
RNS
Publication of VAL401 peer-reviewed article
09 Jan 2019 10:41 AM
RNS
ValiRx endorses the Government's new NHS strategy
03 Jan 2019 07:00 AM
RNS
Holding(s) in Company
18 Dec 2018 04:41 PM
RNS
Second Price Monitoring Extn
18 Dec 2018 04:36 PM
RNS
Price Monitoring Extension
18 Dec 2018 11:25 AM
RNS
Issue of Equity / PDMR Shareholdings
18 Dec 2018 07:00 AM
RNS
Update on VAL401 - Peer-review Acceptance
10 Dec 2018 07:00 AM
RNS
Update on VAL201 Clinical Trial
05 Nov 2018 07:00 AM
RNS
Re scientific and investor meetings
01 Nov 2018 07:15 AM
EQS
ValiRx (VAL): VAL401 Phase II trial completed
24 Oct 2018 07:00 AM
RNS
Align Research Initiates Coverage
17 Oct 2018 07:00 AM
RNS
VAL201 in concluding stages of Phase I/II trial
15 Oct 2018 12:00 PM
RNS
VAL401 results shortly to be on ClinicalTrials.gov
25 Sep 2018 07:00 AM
RNS
Half-year Report
14 Sep 2018 12:42 PM
RNS
Issue of Equity
06 Sep 2018 07:00 AM
RNS
Update on Clinical Development
24 Jul 2018 12:17 PM
RNS
Result of General Meeting
17 Jul 2018 07:00 AM
RNS
US PATENT GRANT FOR THERAPEUTIC COMPOUND, VAL301
06 Jul 2018 04:42 PM
RNS
Notice of GM
14 Jun 2018 07:00 AM
RNS
VAL401 Update
24 May 2018 09:00 AM
RNS
Price Monitoring Extension
11 May 2018 02:56 PM
RNS
Holding(s) in Company
08 May 2018 12:13 PM
RNS
Result of AGM
04 May 2018 04:40 PM
RNS
Second Price Monitoring Extn
04 May 2018 04:35 PM
RNS
Price Monitoring Extension
04 May 2018 04:01 PM
RNS
Placing and grant of warrants

ValiRx is a fast-growing drug development company focused on identifying novel science with high potential for successful development into products that improve the lives of patients throughout treatment.

ValiRx share price listed on AIM in 2004 under the ticker VAL.

UK 100